[Ip-health] Nature story on Novartis case

[Malini Aisola]

    Petition aims to maintain cheap drugs

*http://www.nature.com/news/2007/070115/full/070115-1.html
**
by *Apoorva Mandavilli
<http://www.nature.com/news/about/aboutus.html#Mandavilli> *
January 15, 2007

Court case in India threatens to derail generic medicines.*

The international humanitarian group Doctors Without Borders (M=E9decins
Sans Fronti=E8res, or MSF) is ramping up their fight against the Swiss
drug giant Novartis, urging the company to drop a lawsuit that could
make it much more difficult for Indian companies to produce cheap,
generic drugs.

With the case expected to come up for hearing on 29 January, MSF is
pumping up efforts to collect signatures on a petition against the suit.
Already they have tens of thousands of names, but are aiming to get many
more. A win for the pharmaceutical company, they say, would deprive the
world's poorest people of affordable medicines.

Indian companies are known for making low-cost copies of expensive
medicines, particularly AIDS drugs. More than half of the antiretroviral
drugs used in developing countries, and about 80% of those provided by
MSF, are made by Indian companies. "India is the pharmacy for the
developing world," says Ellen 't Hoen, director of policy advocacy for
MSF's Campaign for Access to Essential Medicines. "We largely depend on
India."

India's laws currently don't allow drug companies to patent products
that are seen to be simply new derivatives or combinations of existing
drugs. This frees up local companies to do a booming trade in
inexpensive copies of the non-patented formulations.

In January 2006, Novartis was denied a patent by a court in the southern
Indian city of Chennai for their cancer drug Glivec, after the drug was
deemed a variation of a previously patented substance.

But Novartis disagrees with the decision. In May, the company filed
petitions against the Indian government and the Indian Patent Office,
claiming that the ruling violates World Trade Organization rules on
patents.

MSF and other activist groups fear that if Novartis wins, an increase in
patented drugs in India will mean fewer generics for all.

*All for one*

Other companies have remained on the sidelines of this court case, but a
victory for Novartis would benefit all multinational companies, says 't
Hoen. "I think they're all watching because none of them are happy with
that part of the law," she says.

So far, at least, Novartis is standing firm. "We don't agree with the
petition," says Paul Herrling, head of corporate research for Novartis.
"It's our democratic right to appeal to a court."

The last time MSF took on such a high-profile fight was in 2001, in
response to 39 companies taking the South African government to court to
prevent the country from importing cheap AsIDS drugs. "This looks very
similar," says 't Hoen.

In that case, MSF collected nearly 300,000 signatures from more than 130
countries. Following public outcry, the companies eventually backed down
and dropped their court case.

But there have been other instances when companies have won, notes James
Love, director of the Consumer Project on Technology in Washington DC.
"Sometimes protest works, sometimes it doesn't," Love says. "But there's
only so much heat the companies can take."







--

Malini Aisola

malini.aisola@cptech.org

www.cptech.org


Consumer Project on Technology

1621 Connecticut Ave, NW, Washington, DC 20009 USA

Tel.:  +1.202.332.2670 Fax: +1.202.332.2673